TACE plus Nexavar for unresectable HCC improves progression-free survival

Treatment with transarterial chemoembolization and Nexavar improved progression-free survival compared with transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma, according to a study published in Gut.Masatoshi Kudo, MD, PhD, from the Kindai University Faculty of Medicine in Japan, and colleagues explained that because of the high tumor recurrence rate after TACE, the procedure is usually repeated many times, which can lead to deterioration of liver function.To explore the safety and efficacy of combination therapy with Nexavar (sorafenib, Bayer), KudoRead More

Share on facebook
Share on twitter
Share on linkedin